Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia
NCT ID: NCT00493545
Last Updated: 2008-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
24 participants
INTERVENTIONAL
2007-05-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will examine the safety and tolerability of Hsp-E7 and Poly-ICLC administered together as a vaccine for Cervical Intraepithelial neoplasia (CIN). There will be 4 cohorts of subjects in the study each given a higher dose than the one prior providing that prior dose has been well tolerated and deemed to be safe.
Subjects will be immunized every 28 days for a period of 8 weeks (3 administrations).
Posttreatment evaluation will occur 4 weeks after the last of 3 injections. Subjects with CIN 2 or 3 disease at the time of enrollment will be eligible to undergo clinically appropriate therapeutic treatment of the cervix at the twelfth of the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HspE7 and Poly-ICLC
3 injections of HspE7 and Poly ICLC given every 28 days for 3 injections
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Nonpregnant, Nonlactating female greater than or equal to 18 years of age, who is either surgically sterile, postmenopausal (no menses for the previous 12 months), or practices an effective method of birth control (to be continued throughout the study period) as determined by the Investigator (eg: oral contraceptives, injectables or implants, intrauterine device, double-barrier methods). The use of cervical cap or diaphram is not permitted).
3. Geographically accessible for ongoing follow up and committed to comply with all visits.
4. Judged to be in good health based upon the results of a medical history, physical examination, vital signs and laboratory profile.
5. Capable of understanding and complying with the protocol and has signed the informed consent.
6. Negative for human immunodeficiency virus (HIV)-1, HIV-2, Hepatitis B surface antigen, and hepatitis C Virus.
Exclusion Criteria
1. Prior exposure to HspE7.
2. The subject received immunotherapy (eg, interferons, tumor necrosis factor, interleukins, or biological response modifiers \[GM CSF, G CSF, M CSF\]) within 4 weeks (28 days) prior to study entry.
3. Taken within 7 days or is currently taking selective Cox-2 inhibitors and other nonsteroidal anti-inflammatory drugs.
4. Received investigational systemic drugs within 4 weeks (28 days) prior to study entry.
5. Undergoing active treatment of genital warts.
6. Has taken astemizole within 7 days prior to study drug administration.
Disease Status:
1. Has an autoimmune disease that in the opinion of the investigator would compromise the safety of the subject in this study. Some examples of autoimmune disease that may be considered exclusionary include rheumatoid arthritis, systematic lupus erythematosus, and autoimmune thyroiditis.
2. Has a recognized immunodeficiency disease, including cellular immunodeficiencies, hypogammaglobulinemia, or dysgammaglobulinemia. The subject has hereditary or congenital immunodeficiencies.
3. Has a positive endocervical curettage at the time of biopsy.
Physiological Functions:
1. Has clinically significant hepatic dysfunction (ie, alanine aminotransferase, aspartate aminotransferase, or total bilirubin ≥1.5 x upper limit of normal (ULN).
2. Has clinically significant renal dysfunction (ie, serum creatinine ≥1.5 x ULN).
3. Has clinically significant cardiac disease, eg, New York Heart Association classes III IV, uncontrolled angina, uncontrolled arrhythmia or uncontrolled hypertension, or myocardial infarction in the previous 6 months as confirmed by an electrocardiogram.
4. Has had a splenectomy.
5. Has an infectious process that in the opinion of the investigator would compromise the subject's ability to mount an immune response.
6. Has a history of severe allergic reaction to insect bites or stings, or to any biologic pharmaceutical product, including compounds similar to the test article.
7. Has donated or lost a significant volume of blood or plasma (greater than 450 mL) within 30 days of the study.
Standard Safety:
1. Is pregnant or breast-feeding, or a woman of childbearing potential unless using effective contraception as determined by the investigator. Subjects whom the investigator considers may be at risk of pregnancy will have a pregnancy test performed per institutional standard.
2. Any other reason that, in the opinion of the investigator, precludes the subject from participating in the study.
3. Known hypersensitivity reaction to any of the components of study treatments.
4. Known alcohol or drug abuse, as assessed by the investigator.
5. Legal incapacity or limited legal capacity.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nventa Biopharmaceuticals Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nventa Biopharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Southern California
Los Angeles, California, United States
Medical Center for Clinical Research
San Diego, California, United States
Medical College of Georgia
Augusta, Georgia, United States
Montefiore Medical Center
New York, New York, United States
University of Oklahoma Health Sciences Center (OUHSC) / OU Medical Center
Oklahoma City, Oklahoma, United States
Baylor College of Medicine
Houston, Texas, United States
Mt Timpanagos Women's Health Center
Pleasant Grove, Utah, United States
Salt Lake Women's Center
South Salt Lake, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HspE7-00101-0601
Identifier Type: -
Identifier Source: org_study_id